Direct answer (40-60 words)
Wegovy was FDA-approved in June 2021, making it nearly 5 years on the market as of April 2026. Its active ingredient (semaglutide) has been used since 2017 under the brand Ozempic for type 2 diabetes. Wegovy uses the same molecule at a higher dose specifically for chronic weight management.
Table of contents
- The 30-second answer
- The full timeline: 2012 to today
- The clinical trial data behind approval (table)
- The 2022 to 2024 supply shortage and its effects
- The 2024 cardiovascular indication expansion
- Wegovy vs Ozempic vs compounded semaglutide
- Long-term safety: what 5 years of data shows
- The current pricing and access landscape
- What's coming next: pipeline updates
- FAQ
- Footer disclaimers
The full timeline: 2012 to today
The history of Wegovy starts before Wegovy itself. Semaglutide's development reflects 30 years of GLP-1 research, beginning with the discovery of GLP-1 itself in 1986.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →2012. Novo Nordisk files the first patents for semaglutide as a long-acting GLP-1 agonist. The molecule is a modified version of the natural GLP-1 hormone, designed to resist degradation by the enzyme DPP-4 and to bind to albumin in the blood, both of which extend half-life from minutes to about a week.
2017 (December). Ozempic (semaglutide 0.5 mg / 1 mg) receives FDA approval for type 2 diabetes. This is the same molecule that becomes Wegovy four years later, just at a different dose.
2018. Rybelsus (oral semaglutide tablets) enters Phase 3 trials. Same molecule, oral formulation.
2020. STEP 1 trial publishes interim results showing 14.9% mean weight loss at 68 weeks for semaglutide 2.4 mg vs 2.4% for placebo. The data is overwhelming enough that the trial becomes the basis of the Wegovy submission to the FDA.
2021 (June 4). The FDA approves Wegovy (semaglutide 2.4 mg once-weekly injection) for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. This is the first new chronic weight management drug approved in 7 years.
2021 (Late). Wegovy launches in the US and immediately faces supply constraints. Demand significantly exceeds Novo Nordisk's manufacturing capacity.
2022 (March). Wegovy is added to the FDA Drug Shortage List. The shortage triggers the legal pathway for compounding pharmacies to produce semaglutide for individual prescriptions.
2022 to 2024. Compounded semaglutide proliferates as patients seek alternatives during the brand-name shortage. Prices range widely.
2023 (March). Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. Tirzepatide is a different molecule (dual GLP-1 + GIP agonist) that becomes the eventual benchmark for weight loss efficacy.
2023 (November). Zepbound (tirzepatide for weight management) is FDA-approved.
2024 (March 8). The FDA expands Wegovy's label to include reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and obesity or overweight. This is based on the SELECT trial (17,604 patients over 4 years).
2024 (October). The FDA declares the Wegovy shortage resolved. Compounded semaglutide is challenged on legal grounds; the legal status of compounded GLP-1 products becomes contested.
2025 (Throughout). Multiple court cases work through the legal status of compounded GLP-1s. The compounding pathway for semaglutide remains restricted under the resolved-shortage framework, though clinical compounding for individualized dosing or medical necessity continues.
2026 (April). Wegovy has been on the market for almost 5 years. Brand-name access has stabilized. Compounded semaglutide remains available through state-licensed pharmacies for individualized prescriptions where clinical need is documented.
The clinical trial data behind approval
The FDA approval of Wegovy was based on the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program, which included 4,500+ patients across multiple Phase 3 trials.
| Trial | Population | Drug | Duration | Mean weight loss | Placebo |
|---|---|---|---|---|---|
| STEP 1 | Adults without diabetes (N = 1,961) | Semaglutide 2.4 mg | 68 weeks | -14.9% | -2.4% |
| STEP 2 | Adults with type 2 diabetes (N = 1,210) | Semaglutide 2.4 mg | 68 weeks | -9.6% | -3.4% |
| STEP 3 | Adults with intensive behavioral therapy (N = 611) | Semaglutide 2.4 mg | 68 weeks | -16.0% | -5.7% |
| STEP 4 | Adults stable on semaglutide (N = 803) | Continued vs switched to placebo | 48 weeks | -7.9% (continuation) | +6.9% (switched) |
| STEP 5 | Adults with obesity (N = 304) | Semaglutide 2.4 mg | 104 weeks | -15.2% | -2.6% |
| SELECT | Adults with prior CV event (N = 17,604) | Semaglutide 2.4 mg | 39.8 months | 20% reduction in MACE | n/a |
The headline number from STEP 1 (14.9% mean weight loss at 68 weeks) was the largest weight loss seen in any chronic weight management drug at that time. STEP 5 extended that to 104 weeks and showed continued effect, addressing the question of whether the weight loss would be sustained.
STEP 4 answered a separate question: what happens if you stop the medication. Patients on continuous semaglutide kept losing weight to a 17% mean. Patients switched to placebo regained about 7% of body weight in 48 weeks. The implication: Wegovy is a chronic medication, not a temporary intervention. Stopping leads to weight regain.
The SELECT trial in 2023 to 2024 added the cardiovascular outcome data: a 20% reduction in major adverse cardiovascular events over almost 4 years. This is the basis of the 2024 label expansion and is the strongest cardiovascular benefit shown for any obesity drug.
The 2022 to 2024 supply shortage and its effects
The Wegovy shortage that began in early 2022 fundamentally shaped the weight-loss medication market. The dynamics:
The cause. Novo Nordisk built manufacturing capacity based on diabetes market demand for Ozempic and was caught off-guard by the obesity demand for Wegovy. Manufacturing semaglutide is a multi-step biological process that takes months to scale.
The impact on patients. Brand-name Wegovy was unavailable or strictly rationed for most of 2022, 2023, and into 2024. Many patients couldn't fill prescriptions. The shortage hit lower doses (the starting and titration doses) hardest, which is the worst possible pattern, because patients can't safely jump to higher doses without titration.
The compounding response. Under federal law (FDCA Section 503A), state-licensed compounding pharmacies can produce a drug copy when the FDA-approved version is on the official drug shortage list. Once Wegovy was added in March 2022, compounded semaglutide became legal for individualized prescriptions.
The market shift. Compounded semaglutide became widely available through telehealth and compounding pharmacies. Prices ranged from $200 to $400 per month for compounded versions vs $1,300+ for brand Wegovy. For uninsured patients or those with high deductibles, compounded was often the only accessible option.
The 2024 resolution. The FDA declared the Wegovy shortage resolved in October 2024. Under FDCA Section 503A, compounding for shortage reasons becomes restricted once the shortage ends. The legal landscape for compounded semaglutide became more complex: clinical compounding (dose individualization, allergen accommodation) remained legal, while bulk shortage-driven compounding was challenged.
The 2025 to 2026 status. Brand Wegovy is generally available. Compounded semaglutide remains accessible through state-licensed pharmacies for individualized clinical need. The pricing gap has narrowed but persists.
The 2024 cardiovascular indication expansion
The March 2024 FDA approval added cardiovascular protection to the Wegovy label, based on the SELECT trial. The trial design and results:
- Population: 17,604 adults with established cardiovascular disease (prior MI, stroke, or peripheral arterial disease) and BMI ≥ 27
- Intervention: Semaglutide 2.4 mg weekly injection vs placebo, on top of standard cardiovascular care
- Duration: Mean follow-up 39.8 months
- Primary endpoint: Time to first major adverse cardiovascular event (MACE: nonfatal MI, nonfatal stroke, cardiovascular death)
- Result: 20% relative risk reduction in MACE (HR 0.80, p < 0.001). Absolute risk: 6.5% on semaglutide vs 8.0% on placebo.
The cardiovascular benefit was independent of weight loss. Patients who lost the least weight still had cardiovascular benefit, suggesting the mechanism includes direct effects on the vasculature, inflammation, or insulin resistance, not just weight reduction alone.
The label expansion gave Wegovy a different position in the market: it's no longer just a weight-loss drug, but a cardiometabolic drug. Insurance coverage that previously rejected weight-loss claims has shifted in some plans to cover Wegovy for cardiovascular protection. This has been the largest single change in patient access since approval.
Wegovy vs Ozempic vs compounded semaglutide
The three forms of semaglutide on the US market:
| Feature | Wegovy | Ozempic | Compounded semaglutide |
|---|---|---|---|
| FDA-approved | Yes (chronic weight management, CV protection) | Yes (type 2 diabetes) | No |
| Active ingredient | Semaglutide | Semaglutide | Semaglutide |
| Maximum dose | 2.4 mg weekly | 2.0 mg weekly | Varies (typically 0.25 to 2.4 mg weekly) |
| Manufacturer | Novo Nordisk | Novo Nordisk | State-licensed compounding pharmacies |
| Insurance coverage | Often covered for obesity or CV protection | Often covered for diabetes | Rarely covered |
| Out-of-pocket cost (approx) | $1,300+ per month list price | $935+ per month list price | $200 to $400 per month |
| Quality oversight | FDA inspection of manufacturing | FDA inspection of manufacturing | State board of pharmacy + USP standards |
| Legal status | FDA-approved | FDA-approved | Legal under FDCA 503A for individualized prescriptions; restricted post-shortage resolution |
A few clarifying points:
- The active ingredient (semaglutide) is the same across all three. Wegovy and Ozempic differ only in dose and indication.
- Compounded semaglutide is not FDA-approved. It's prepared by state-licensed pharmacies under compounding regulations, which have different quality standards than FDA-approved manufacturing. Compounded products are not interchangeable with brand-name versions.
- Recent additives in compounded versions (B12, glycine, levocarnitine) are not part of brand Wegovy. Their efficacy is not separately validated.
For an in-depth look at the calorie side of the equation, see our piece on calorie deficits and finding your number. For more on side effects, see why Zepbound (tirzepatide) causes acid reflux and whether Zepbound can cause anxiety.
Long-term safety: what 5 years of data shows
Five years of post-market surveillance plus the longer trial data (out to 4 years in SELECT, 2 years in STEP 5) gives a reasonable safety picture.
Common side effects (label):
- Nausea (44%)
- Diarrhea (30%)
- Vomiting (24%)
- Constipation (24%)
- Abdominal pain (20%)
- Headache (14%)
- Fatigue (11%)
Most side effects are dose-dependent and improve with longer time at a stable dose. The titration schedule (0.25 mg, then 0.5 mg, 1 mg, 1.7 mg, then 2.4 mg) is designed to manage these.
Serious but rare adverse events:
- Pancreatitis: rare (0.1 to 0.2% over trial periods), comparable to placebo in pooled analyses
- Gallbladder disease: about 2 to 3% in trial populations vs 1% placebo, related to rapid weight loss
- Thyroid C-cell tumors: theoretical risk based on rodent studies. Has not been demonstrated in humans. Boxed warning on the label remains.
- Severe hypoglycemia: very rare in non-diabetic patients
- Diabetic retinopathy: small risk in patients with type 2 diabetes during rapid HbA1c reduction
Discontinuation rates:
- About 7% of patients in STEP 1 discontinued due to adverse events vs 3% on placebo. Most discontinuations were GI-related.
Pregnancy and lactation:
- Not recommended during pregnancy. The 2-month washout before conception attempt is the current advice.
- Limited safety data in lactation; generally avoided.
Long-term cancer risk:
- The SELECT trial had 4 years of follow-up and didn't show a cancer signal. The thyroid C-cell signal from rodent studies remains unconfirmed in humans.
- Ongoing FDA surveillance through FAERS continues. As of April 2026, no causal cancer association has been established.
The overall safety profile after 5 years is consistent with the expected GLP-1 class profile. The main long-term consideration is that Wegovy is essentially a chronic medication. Stopping leads to weight regain, so the drug-vs-disease tradeoff is ongoing rather than time-limited.
The current pricing and access landscape
As of April 2026:
- Wegovy list price: $1,349 per month
- Cash-pay programs (Novo Nordisk direct): $499 per month for some doses
- Insurance coverage for weight-loss indication: Approximately 40 to 50% of commercial plans
- Insurance coverage for cardiovascular indication: Approximately 65 to 75% of plans
- Medicare coverage: Allowed for cardiovascular indication; not for weight loss alone
- Compounded semaglutide: Available through state-licensed pharmacies for individualized prescriptions; pricing $200 to $400 per month typical
The 2024 cardiovascular label expansion materially changed access. Patients with prior MI, stroke, or established CV disease can often get coverage that wasn't available for weight loss alone. The eligibility window has widened.
Out-of-pocket costs vary widely depending on insurance status, employer plan, and the specific indication on the prescription. Patients should check their plan's prior authorization requirements before assuming coverage.
What's coming next: pipeline updates
As of April 2026, the GLP-1 obesity pipeline includes:
- Oral semaglutide for obesity (Novo Nordisk): Phase 3 OASIS trials completed; FDA submission in process. An oral version of Wegovy is expected to launch in late 2026 or 2027.
- Retatrutide (Eli Lilly): Triple agonist (GLP-1 + GIP + glucagon receptor). Phase 3 data showed up to 24% mean weight loss at 48 weeks. FDA submission expected 2026.
- CagriSema (Novo Nordisk): Combination of semaglutide and cagrilintide (an amylin analog). Phase 3 results showed approximately 22% mean weight loss.
- Several oral small-molecule GLP-1 agonists in early Phase 2 trials.
The trajectory suggests that Wegovy, while still effective, will be a middle-tier option within 2 to 3 years. Newer drugs with greater efficacy and oral formulations are likely to displace it for many patients.
FAQ
How long has Wegovy been on the market?
Wegovy was FDA-approved on June 4, 2021, making it nearly 5 years on the market as of April 2026. The active ingredient, semaglutide, has been on the market since December 2017 under the brand Ozempic for type 2 diabetes.
When was Wegovy approved by the FDA?
The FDA approved Wegovy on June 4, 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The approval was expanded in March 2024 to include reduction of major adverse cardiovascular events.
Is Wegovy a new drug?
Wegovy itself is relatively new (approved in 2021), but its active ingredient (semaglutide) has been used in humans since the 2018 launch of Ozempic for diabetes. The molecule has been in clinical trials since 2012.
How much weight do people lose on Wegovy?
In the STEP 1 trial, mean weight loss at 68 weeks was 14.9% of body weight on semaglutide 2.4 mg vs 2.4% on placebo. STEP 5 (104 weeks) showed sustained 15.2% mean loss. Real-world results are generally somewhat lower because of imperfect adherence.
How does Wegovy work?
Wegovy mimics the natural hormone GLP-1, slowing gastric emptying and suppressing appetite signaling in the hypothalamus. The result is reduced food intake and a sustained calorie deficit.
Is there a generic for Wegovy?
No. Semaglutide patents are still active. The earliest expected generic semaglutide is around 2031, though patent challenges may shift the date. Compounded semaglutide is available but is not a generic and is not FDA-approved.
Is Wegovy the same as Ozempic?
The active ingredient is the same (semaglutide), but Wegovy is dosed up to 2.4 mg weekly for weight loss while Ozempic is dosed up to 2.0 mg weekly for diabetes. Wegovy is FDA-approved for chronic weight management and cardiovascular protection. Ozempic is FDA-approved for type 2 diabetes.
Is Wegovy safe for long-term use?
Long-term data through 4 years (SELECT trial) and 2 years (STEP 5) shows the safety profile remains stable, with most adverse events occurring in the first 8 to 16 weeks. Wegovy is intended as a chronic medication, similar to medications for blood pressure or cholesterol.
Why was Wegovy in shortage?
Demand significantly exceeded Novo Nordisk's manufacturing capacity from 2022 through 2024. The shortage was officially resolved by the FDA in October 2024 after manufacturing scale-up.
Has Wegovy been used in real-world settings for 5 years?
Yes. The launch was June 2021, so the medication has been in real-world use for almost 5 years. Post-marketing surveillance through FAERS has not surfaced new safety signals beyond the trial data.
Is Wegovy approved for cardiovascular protection?
Yes, since March 2024. The FDA expanded the label based on the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events over almost 4 years.
Who can take Wegovy?
Adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity, are eligible for the weight-management indication. Adults with established cardiovascular disease and BMI ≥ 27 are eligible for the cardiovascular indication.
How is Wegovy different from compounded semaglutide?
Wegovy is FDA-approved and manufactured under FDA-inspected facilities. Compounded semaglutide is prepared by state-licensed pharmacies and is not FDA-approved. The active ingredient is the same, but the products are not interchangeable. Compounded versions sometimes contain additives (B12, glycine) not present in brand Wegovy.
Author / review note
Reviewed by the FormBlends Medical Team. References include the FDA approval letter for Wegovy (NDA 215256, June 4, 2021), Wilding et al., NEJM, 2021 (STEP 1), Garvey et al., Nature Medicine, 2022 (STEP 5), Lincoff et al., NEJM, 2023 (SELECT), and the FDA Drug Shortages database history for semaglutide injection.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →